Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Douglas Tsao reiterates Outlook Therapeutics (NASDAQ:OTLK) with a Neutral and maintains $1 p...
Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and lowers the price target fr...
Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizuma...
Guggenheim analyst Eddie Hickman downgrades Outlook Therapeutics (NASDAQ:OTLK) from Buy to Neutral.
HC Wainwright & Co. analyst Douglas Tsao downgrades Outlook Therapeutics (NASDAQ:OTLK) from Buy to Neutral and announces...
Chardan Capital analyst Daniil Gataulin maintains Outlook Therapeutics (NASDAQ:OTLK) with a Neutral and maintains $3 price t...
